The Biomedical Accelerator Fund
New inventions made by scientists in an academic environment are often at an early-stage of development. While showing great promise, many of these innovations languish or lie dormant due to the lack of compelling "proof-of-principle" data needed to secure the funding required for continued development and commercialization. As a result, many new technologies with potential to save lives and benefit society never make it out of the lab.
Harvard University is continually seeking innovative ways to address this development gap between early stage research and attractive, investment- and venture-grade opportunities. To this end, Harvard has launched a novel Biomedical Accelerator Fund, a dedicated program to award development gap funding to Harvard investigators, thereby fostering and advancing the development of nascent technologies emanating from university labs into commercial development and, ultimately, the global marketplace.
Benefits of the Biomedical Accelerator Fund
- Accelerates and propels promising new discoveries from the lab to the commercial development stage
- Builds added value into early-stage technologies, thereby enhancing their commercial viability
- Overcomes many of the limitations that impede potentially life-altering technologies from reaching their full potential
-
Creates more attractive opportunities for licensing, investment and commercial development
- Expands public access to new technologies developed at Harvard
- Reinforces Harvard's mission and commitment to serve the public interest